Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Active, not recruiting · NCT03190915 · Registry updated 2026-07-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, bone marrow disorder, hematologic disorder, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, juvenile myelomonocytic leukemia, leukemia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neurofibroma, neurofibromatosis, neurofibromatosis type 1, neuromuscular disease, peripheral nervous system disorder | Active, not recruiting | Phase 2 | 2026-07-20 | NCT03190915 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Children's Oncology Group | 79 |
| National Cancer Institute (NCI) | 3015 |
57 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.